Skin Cancer

SKNJCT-003 is expected to enroll up to 60 patients.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in skin cancer this year.

The study examined the mechanisms of action associated with immune checkpoint inhibitor combination therapies.

The Society for Immunotherapy of Cancer recently published insights into the management of patients with preexisting autoimmune disease, solid organ transplant recipients, elderly individuals, those living with HIV, pregnant patients, and those with rare noncutaneous subtypes of melanoma.

Click here to answer this week's poll about a recent FDA Complete Response Letter.

At 3 years, V940 plus pembrolizumab reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62%.

One of the specific areas of focus will be non-melanoma skin cancer.

Investigators used LIMS to classify melanoma samples as tumors and non-tumors.

Click here to answer this week's skin cancer poll.

A review examined the treatment landscape of BCC, particularly in the realm of photodynamic therapy.

With artificial intelligence taking front and center in many aspects of our lives, will it be more prevalent in the dermatology practice than it is now?

The addition of bemcentinib to the standard-of-care therapies of pembrolizumab or dabrafenib plus trametinib was well tolerated in patients with metastatic melanoma; however, it did not lead to improvements in overall response rate, progression-free survival, or overall survival vs SOC alone.

Each of 3 patients treated with cemiplimab achieved a near complete response.

Identifying social determinants in TEM is crucial to eliminating disparities in care, study authors wrote.

Immunotherapies, including PD-1 checkpoint inhibitors such as nivolumab, have improved the treatment options for patients with advanced melanoma.

Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma.

Study results were presented at the 2023 American Society for Dermatologic Surgery Annual Meeting in Chicago, Illinois.

Click here to answer this week's skin cancer poll.

ChatGPT shows promise in dermatology but needs improvement in accuracy and conciseness for reliable clinical use, according to a study evaluating its performance in actinic keratosis management.

A poster presented at SDPA’s fall conference revealed key insights into the importance of close monitoring and preventative measures in patients with cSCC.

Orit Markowitz, MD, discusses pearls her SDPA fall conference sessions, "Melanoma Diagnosis, Outcomes and Survival," and "Advanced Conditions."

The goal of Arron et al’s study was to determine if the 40-GEP test could identify high-risk cSCC patients who would benefit from ART in controlling metastatic disease progression.

Farberg is looking forward to another year of top-notch presentations at Fall Clinical 2023.

The advancement is based on previous observations of preliminary clinical efficacy. There are currently no FDA-approved therapies for this patient population.

Approval is based on data from Bristol Myers Squibb’s CheckMate – 76K trial.

Aaron Farberg, MD, and Shanna Miranti, MPAS, PA-C, discuss the upcoming approvals of nivolumab and IDP-126.

Greater treatment costs are associated with more advanced stages of melanoma, particularly due to increasing prices of treatments.

Click here to answer this week's skin cancer poll.

Surgical removal techniques including Mohs surgery and excisional surgery are preferred treatment approach when addressing BCCs, particularly on the hands.

Dermatologist Laura Ferris, MD, PhD, discusses skin-related toxicities as a result of immunotherapies for the treatment and management of cancers.